title: Transfer of high cost drugs to NICE risks fragmentation of care of rare diseases.
authors.forename: Chris J
authors.initials: CJ
authors.lastname: Hendriksz
authors.forename: D A
authors.initials: DA
authors.lastname: Hughes
authors.forename: A B
authors.initials: AB
authors.lastname: Mehta
authors.forename: J E
authors.initials: JE
authors.lastname: Wraith
authors.forename: S E
authors.initials: SE
authors.lastname: Jones
authors.forename: U
authors.initials: U
authors.lastname: Ramaswami
authors.forename: P
authors.initials: P
authors.lastname: Deegan
authors.forename: R
authors.initials: R
authors.lastname: Lachmann
authors.forename: E
authors.initials: E
authors.lastname: Murphy
authors.forename: T
authors.initials: T
authors.lastname: Hiwot
authors.forename: S V
authors.initials: SV
authors.lastname: Vijay
authors.forename: F
authors.initials: F
authors.lastname: Stewart
authors.forename: M
authors.initials: M
authors.lastname: Cleary
mesh_terms: D016527:Drug Costs; D006801:Humans; D011785:Quality Assurance, Health Care / Q000458:organization & administration; D035583:Rare Diseases / Q000191:economics / Q000628:therapy; D020414:Risk Sharing, Financial / Q000379:methods*; D006113:United Kingdom